Deflazacort oral suspension is a medication used to treat certain types of muscular dystrophy. It is available in various formulations, including a tablet and an oral suspension [1]. The oral suspension form can be particularly useful for patients who have difficulty swallowing pills [2].
What is Deflazacort used for?
Deflazacort is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older [1][3]. DMD is a genetic disorder characterized by progressive muscle weakness and degeneration [4]. By reducing inflammation, deflazacort helps to slow the progression of muscle loss in DMD patients [5].
How does Deflazacort oral suspension work?
Deflazacort is a corticosteroid, a type of drug that reduces inflammation [5]. It works by suppressing the immune system's inflammatory response. In the context of muscular dystrophy, this anti-inflammatory action is believed to help preserve muscle function and strength [4][5].
What are the potential side effects of Deflazacort oral suspension?
Common side effects associated with deflazacort treatment include weight gain, increased appetite, facial rounding (Cushingoid appearance), and infections [3]. Other potential side effects can include elevated blood pressure, mood changes, bone density loss, and cataracts [3][6]. Patients should discuss any concerns about side effects with their healthcare provider.
When does Deflazacort's patent expire?
Information regarding specific patent expiry dates for deflazacort can be found on specialized drug patent databases. For example, DrugPatentWatch.com provides details on patent statuses and expiration timelines for pharmaceuticals [7].
Who makes Deflazacort oral suspension?
Several pharmaceutical companies manufacture and market deflazacort. The specific brand names and manufacturers can vary by region. For instance, Emflaza is a brand name for deflazacort in the United States, and it is marketed by PTC Therapeutics [1].
What are the alternatives to Deflazacort for muscular dystrophy?
While deflazacort is approved for DMD, other treatment approaches exist, including supportive care and emerging gene therapies. The choice of treatment depends on the specific type and stage of muscular dystrophy, as well as individual patient factors [4][8].
How does Deflazacort compare to other corticosteroids?
Deflazacort is a glucocorticoid, similar to prednisone and prednisolone, which are also used to manage inflammation in various conditions, including some forms of muscular dystrophy [5][9]. While they share mechanisms of action, their specific profiles regarding efficacy and side effects may differ [5].
What clinical data supports the use of Deflazacort in DMD?
Clinical trials have demonstrated that deflazacort can slow the loss of ambulation and improve muscle strength in boys with Duchenne muscular dystrophy [5]. These studies have been instrumental in its approval for this indication.
Sources:
[1] https://www.emflaza.com/
[2] https://www.medicalnewstoday.com/articles/325304
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209024Orig1s000lbl.pdf
[4] https://www.ninds.nih.gov/health-information/disorders/muscular-dystrophy
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1607242
[6] https://www.drugs.com/sfx/deflazacort-side-effects.html
[7] https://drugpatentwatch.com/
[8] https://www.treat-nmd.org/
[9] https://www.ncbi.nlm.nih.gov/books/NBK538376/